Fund Holdings — EcoR1 Capital, LLC

Total Portfolio Value:
$2.02B
Total Bought:
$225.41M
Total Sold:
$777.15M
Net Transaction:
-$551.74M
Notable People:
Scott Eric Perlen
Securities
▲▼
SharesValue
Q1 2026
▲▼
Q2 2026
▲▼
Change
▲▼
Q1 2026
▲▼
Q2 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Zymeworks Inc.(ZYME)22,970,38822,970,3880$575.18M$600.45M29.77%+$25.27M
Anaptysbio Inc7,880,0947,880,0940$437.03M$531.91M26.37%+$94.88M
Aktis Oncology, Inc.(AKTS)4,824,4694,824,4690$86.31M$155.49M7.71%+$69.18M
CG Oncology, Inc.(CGON)1,102,0001,494,300+392,300$74.58M$106.17M5.26%+$31.59M
Eton Pharmaceuticals, Inc.(ETON)2,171,9382,171,9380$53.60M$78.62M3.90%+$25.02M
CRISPR Therapeutics AGNAMEN AKT(CRSP)1,389,2761,389,2760$66.09M$75.77M3.76%+$9.68M
ORIC Pharmaceuticals, Inc.(ORIC)6,728,1166,728,1160$85.25M$72.87M3.61%-$12.38M
First Tracks BiotherapeuticsORD SHS ADDED03,174,519+3,174,519$0$63.87M3.17%+$63.87M
Lakefront Biotherapeutics NVADR(LKFT)1,667,1191,667,1190$50.01M$49.98M2.48%-$33.3K
Neurogene Inc.(NGNE)1,271,3421,271,3420$25.63M$39.98M1.98%+$14.35M
Stoke Therapeutics, Inc.(STOK)100,000735,000+635,000$3.26M$24.05M1.19%+$20.79M
Fulcrum Therapeutics, Inc.(FULC)06,549,866+6,549,866$0$23.97M1.19%+$23.97M
Legend Biotech CorporationADS(LEGN)0800,000+800,000$0$23.10M1.15%+$23.10M
BridgeBio Oncology Therapeutics, Inc.(BBOT)2,823,1262,823,1260$25.27M$21.51M1.07%-$3.75M
MBX Biosciences, Inc.(MBX)777,000388,500-388,500$23.19M$21.45M1.06%-$1.75M
Zenas BioPharma, Inc.(ZBIO)789,500789,5000$15.43M$20.04M0.99%+$4.60M
Atara Biotherapeutics Inc99,5931,552,000+1,452,407$471.1K$17.82M0.88%+$17.35M
Relay Therapeutics, Inc.(RLAY)1,904,762697,948-1,206,814$18.95M$13.06M0.65%-$5.89M
Aura Biosciences, Inc.(AURA)01,666,667+1,666,667$0$11.83M0.59%+$11.83M
Odyssey Therapeutics IncCOMMON STOCK ADDED0555,555+555,555$0$10.39M0.52%+$10.39M
Eikon Therapeutics, Inc.(EIKN)732,606732,6060$7.75M$9.56M0.47%+$1.81M
Pharvaris N V
COM
0235,000+235,000$0$8.13M0.40%+$8.13M
Zura Bio LimitedCL A(ZURA)1,179,7151,179,7150$7.02M$6.96M0.35%-$59.0K
Phathom Pharmaceuticals, Inc.(PHAT)625,000625,0000$6.94M$6.78M0.34%-$162.5K
Nurix Therapeutics, Inc.(NRIX)0270,000+270,000$0$6.55M0.32%+$6.55M
Erasca, Inc.(ERAS)900,000330,000-570,000$14.56M$6.05M0.30%-$8.52M
Eloxx Pharmaceuticals IncCOM NEW ADDED0400,000+400,000$0$5.55M0.28%+$5.55M
Aardvark Therapeutics Inc0396,194+396,194$0$2.28M0.11%+$2.28M
Helix Acquisition Corp. IIICL A(HLXC)200,000200,0000$2.03M$2.13M0.11%+$96.0K
Mereo BioPharma Group plcADS(MREO)13,368,8551,000,000-12,368,855$4.41M$317.7K0.02%-$4.09M
Surrozen, Inc.W EXP 08 01 203(SRZN)4,4444,4440$129.5K$115.3K0.01%-$14.1K
Centessa Pharmaceuticals PlcADS6,000,0000-6,000,000$238.32M$0—-$238.32M
Crinetics Pharmaceuticals In4,288,1200-4,288,120$155.74M$0—-$155.74M
iBio, Inc.(IBIO)1,583,0000-1,583,000$3.01M$0—-$3.01M
Jazz Pharmaceuticals plcSHS USD(JAZZ)1,706,4690-1,706,469$322.61M$0—-$322.61M
Prelude Therapeutics Incorporated(PRLD)947,0490-947,049$3.24M$0—-$3.24M
Replimune Group, Inc.(REPL)1,000,0000-1,000,000$7.65M$0—-$7.65M
Xencor, Inc.(XNCR)2,183,0000-2,183,000$26.33M$0—-$26.33M
Page 1 of 1
EcoR1 Capital, LLC — 13F Holdings — Q2 2026 | TickerTrail